Bacterial culture detection and identification in blood agar plates with an optoelectronic nose

Lim, Sung Hee; Mix, Samantha; Anikst, Victoria; Budvytiene, Indre; Eiden, Michael; Churi, Yair S.; Queraltó, Núria; Berliner, Anders; Martino, Raymond A.; Rhodes, Paul; Banaei, Niaz

doi:10.1039/c5an01990g

Cited by 39 publications

(23 citation statements)

References 41 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many breath volatile and non-volatile compounds are product of bacterial metabolism (Airoldi et al, 2016). Moreover, breathomics techniques, including e-noses and NMR spectroscopy, can be used for detecting and identifying bacterial species (Lim et al, 2016; Palama et al, 2016). For these reasons, exhaled breath analysis has been proposed as a powerful tool to identify bacterial metabolomic signatures (Airoldi et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD

Montuschi

Santini

et al. 2018

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Prospective pharmacological studies on breathomics profiles in COPD patients have not been previously reported. We assessed the effects of treatment and withdrawal of an extrafine inhaled corticosteroid (ICS)-long-acting β2-agonist (LABA) fixed dose combination (FDC) using a multidimensional classification model including breathomics.Methods: A pilot, proof-of-concept, pharmacological study was undertaken in 14 COPD patients on maintenance treatment with inhaled fluticasone propionate/salmeterol (500/50 μg b.i.d.) for at least 8 weeks (visit 1). Patients received 2-week treatment with inhaled beclomethasone dipropionate/formoterol (100/6 μg b.i.d.) (visit 2), 4-week treatment with formoterol alone (6 μg b.i.d.) (visit 3), and 4-week treatment with beclomethasone/formoterol (100/6 μg b.i.d.) (visit 4). Exhaled breath analysis with two e-noses, based on different technologies, and exhaled breath condensate (EBC) NMR-based metabolomics were performed. Sputum cell counts, sputum supernatant and EBC prostaglandin E2 (PGE2) and 15-F2t-isoprostane, fraction of exhaled nitric oxide, and spirometry were measured.Results: Compared with formoterol alone, EBC acetate and sputum PGE2, reflecting airway inflammation, were reduced after 4-week beclomethasone/formoterol. Three independent breathomics techniques showed that extrafine beclomethasone/formoterol short-term treatment was associated with different breathprints compared with regular fluticasone propionate/salmeterol. Either ICS/LABA FDC vs. formoterol alone was associated with increased pre-bronchodilator FEF25−75% and FEV1/FVC (P = 0.008–0.029). The multidimensional model distinguished fluticasone propionate/salmeterol vs. beclomethasone/formoterol, fluticasone propionate/salmeterol vs. formoterol, and formoterol vs. beclomethasone/formoterol (accuracy > 70%, P < 0.01).Conclusions: Breathomics could be used for assessing ICS treatment and withdrawal in COPD patients. Large, controlled, prospective pharmacological trials are required to clarify the biological implications of breathomics changes. EUDRACT number: 2012-001749-42.

show abstract

Section: Discussionmentioning

confidence: 99%

Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD

Montuschi

Santini

et al. 2018

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…An agar-filled petri dish is inoculated with the sample and the array is placed the in a petri dish lid; as the bacteria grow, the VOCs produced cause a distinctive pattern of colour changes that can be read by scanner or smartphone camera for analysis 116 . Testing of colorimetric sensor arrays with blood agar plate culture of clinical isolates or blood culture showed ~91% sensitivity and ~99% specificity 117,118 . However, for point-of-care screening, systems for detecting bacteriuria based on VOCs will have to be tested directly with urine samples and interpretation of results could be confounded by the variability of VOCs in urine.…”

Section: Emerging Diagnostic Platformsmentioning

confidence: 99%

New and developing diagnostic technologies for urinary tract infections

et al. 2017

Self Cite

View full text Add to dashboard Cite

Timely and accurate identification and determination of the antimicrobial susceptibility of uropathogens is central to the management of UTIs. Urine dipsticks are fast and amenable to point-of-care testing, but do not have adequate diagnostic accuracy or provide microbiological diagnosis. Urine culture with antimicrobial susceptibility testing takes 2 3 days and requires a clinical laboratory. The common use of empirical antibiotics has contributed to the rise of multidrug-resistant organisms, reducing treatment options and increasing costs. In addition to improved antimicrobial stewardship and the development of new antimicrobials, novel diagnostics are needed for timely microbial identification and determination of antimicrobial susceptibilities. New diagnostic platforms, including nucleic acid tests and mass spectrometry, have been approved for clinical use and have improved the speed and accuracy of pathogen identification from primary cultures. Optimization for direct urine testing would reduce the time to diagnosis, yet these technologies do not provide comprehensive information on antimicrobial susceptibility. Emerging technologies including biosensors, microfluidics, and other integrated platforms could improve UTI diagnosis via direct pathogen detection from urine samples, rapid antimicrobial susceptibility testing, and point-of-care testing. Successful development and implementation of these technologies has the potential to usher in an era of precision medicine to improve patient care and public health.

show abstract

“…Among these, a disposable colorimetric sensor array (CSA) has been shown to identify a panel of pathogenic bacteria with great accuracy [16–19]. The promise of this low cost technology is that it is rapid, with identification obtained automatically during culture, saving time, labor, and cost.…”

Section: Introductionmentioning

confidence: 99%

The combined rapid detection and species-level identification of yeasts in simulated blood culture using a colorimetric sensor array

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundA colorimetric sensor array (CSA) has been demonstrated to rapidly detect and identify bacteria growing in blood cultures by obtaining a species-specific “fingerprint” of the volatile organic compounds (VOCs) produced during growth. This capability has been demonstrated in prokaryotes, but has not been reported for eukaryotic cells growing in culture. The purpose of this study was to explore if a disposable CSA could differentially identify 7 species of pathogenic yeasts growing in blood culture.MethodsCulture trials of whole blood inoculated with a panel of clinically important pathogenic yeasts at four different microorganism loads were performed. Cultures were done in both standard BacT/Alert and CSA-embedded bottles, after adding 10 mL of spiked blood to each bottle. Color changes in the CSA were captured as images by an optical scanner at defined time intervals. The captured images were analyzed to identify the yeast species. Time to detection by the CSA was compared to that in the BacT/Alert system.ResultsOne hundred sixty-two yeast culture trials were performed, including strains of several species of Candida (Ca. albicans, Ca. glabrata, Ca. parapsilosis, and Ca. tropicalis), Clavispora (synonym Candida) lusitaniae, Pichia kudriavzevii (synonym Candida krusei) and Cryptococcus neoformans, at loads of 8.2 × 105, 8.3 × 103, 8.5 × 101, and 1.7 CFU/mL. In addition, 8 negative trials (no yeast) were conducted. All negative trials were correctly identified as negative, and all positive trials were detected. Colorimetric responses were species-specific and did not vary by inoculum load over the 500000-fold range of loads tested, allowing for accurate species-level identification. The mean sensitivity for species-level identification by CSA was 74% at detection, and increased with time, reaching almost 95% at 4 hours after detection. At an inoculum load of 1.7 CFU/mL, mean time to detection with the CSA was 6.8 hours (17%) less than with the BacT/Alert platform.ConclusionThe CSA combined rapid detection of pathogenic yeasts in blood culture with accurate species-level identification.

show abstract

Bacterial culture detection and identification in blood agar plates with an optoelectronic nose

Cited by 39 publications

References 41 publications

Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD

Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD

New and developing diagnostic technologies for urinary tract infections

The combined rapid detection and species-level identification of yeasts in simulated blood culture using a colorimetric sensor array

Contact Info

Product

Resources

About